ResMed has forecast the recall at its competitor Philips will add up to $350 million to its sales of sleep apnea and ventilator devices over the next 12 months.
Philips unveils MRI tech for total heart scans in under 1 minute
The Federal Circuit exhibited the current status of its obviousness jurisprudence in affirming the District Court's determination that the asserted claims of U.S. Patent No. 8,410,131 were not obvious in a decision handed down this week in Novartis Pharmaceuticals Corp. v. West-Ward Pharmaceuticals Int'l.
Hikma has already cut 200 jobs since picking up generics business Roxane Labs from Boehringer Ingelheim, but more layoffs are coming.
Roxane Laboratories, Inc.; Withdrawal of Approval of a New Drug Application for ROXICODONE (Oxycodone Hydrochloride) Sustained-Release Tablets, 10 Milligrams and 30 Milligrams
Roxane’s Generic Flucytosine Receives Approval In US
Law360, Los Angeles (May 10, 2017, 7:36 PM EDT) -- Astellas Pharma Inc. is accusing Roxane Laboratories Inc. of filing an abbreviated new drug application for a generic version of its prostate cancer treatment Xtandi that infringes three of its unexpired patents, according to a complaint filed in Delaware federal court Tuesday.
The company today confirmed a report from IN THE PIPELINE that it had reduced its payroll by about 244 additional positions in the U.S. since July 1, most of those in Connecticut where the company has its U.S. headquarters. According to the statement emailed to FiercePharma, it will add a new R&D group in the state next year that will have about 35 employees.
Jordan-based Hikma laid out a couple of billion dollars in cash and stock this year to buy Boehringer Ingelheim’s U.S. generic drug business Roxane Laboratories and says that addition is already transforming its own generics operations. And Hikma thinks it can squeeze some additional juice out of the deal by using a plant it acquired in the deal for contract manufacturing.